Last updated
Teva Pharmaceuticals: M&A Activity
Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.
Source: STAT News (Pharmalot)
- Who
- Teva Pharmaceuticals · Biotech & Pharma · Australia & New Zealand
- What happened
- Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.
- When
- 2026-07-14
- Source
- STAT News (Pharmalot)
Market context: MitchelLake's Talent Market Index sits at 95.4 (Cool), down 5.3 on the prior month; Oceania hiring signal is running rising (+8.2pts).
Teva Pharmaceuticals: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 31 tracked companies; 0.1% of MitchelLake's Oceania signal flow; 4 tracked across 50 days.
MitchelLake in this thematic
Also at Teva Pharmaceuticals →
More signals across Biotech & Pharma
M&A Activity · Oceania
UCB →UCB completed $2B acquisition of Candid Therapeutics, acquiring two clinical-stage T cell engagers for autoimmune disorders
Partnership · Oceania
NeuroScientific Biopharmaceuticals →NeuroScientific Biopharmaceuticals has engaged Southern Star Research to conduct a phase two clinical trial of its StemSmart Crohn's disease therapy in Australia and the US.
Partnership · Oceania
AusBiotech →AusBiotech announced a strategic partnership with Tenmile venture capital firm to strengthen ecosystem connections and help Australian health startups access both domestic and international capital. The partnership extends prior collaboration on the Early Stage Innovation Forum and creates additional opportunities for startups and scale-ups.
M&A Activity · Americas
Repligen Corporation →Repligen completed acquisition of BioLife Solutions for $11.25/share cash plus stock consideration. Transaction consolidates cell therapy bioprocessing capabilities and expands Repligen's product portfolio in high-growth cell and gene therapy market.
M&A Activity · Americas
Amgen →Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.
M&A Activity · Americas
BioMarin Pharmaceutical Inc. →BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.
Where this lands in our work
- Private Equity →
Ownership change resets the executive requirement — value-creation leadership follows the deal.
- Executive Search: Oceania →
Our Oceania practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record
